India’s Aurobindo Pharma to Expand New Jersey Facility

At its current New Jersey facility,  the company makes non-penicillin and non-cephalosporin products. The bulk of its U.S. supply comes from India, where it has six plants. It gets more than half its total revenue from selling drugs for HIV/AIDS, asthma, and schizophrenia, among others, to the U.S.

India’s drug industry is worth about $15 billion and it supplies roughly 30 percent of the medicines sold in the U.S. reports Business Line.

Be Sociable, Share!
Posted on by Gunjan Bagla
Gunjan Bagla
California-based management consultant Gunjan Bagla runs Amritt, a consulting firm helping American companies to succeed in India. Amritt is the trusted advisor for India market research, India business development, India market entry, Global Engineering, Global Technology Scouting, India R&D and Open Innovation. Gunjan is author of "Business in 21st Century India: How to Profit Today from Tomorrow’s Most Exciting Market" (Hachette Book Group, 2008), Amazon's top rated title on the subject. He has appeared as the India Expert on BBC Television, Bloomberg TV, Fox Cable Business and has been quoted in the New York Times, the Los Angeles Times, the Hollywood Reporter and Business Week for his expertise on India.

0 comments

There are no comments yet...

Kick things off by filling out the form below.

Leave a Comment

*